Puzo Michael J Acquires 55 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Puzo Michael J boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,340 shares of the pharmaceutical company’s stock after buying an additional 55 shares during the period. Vertex Pharmaceuticals makes up about 1.9% of Puzo Michael J’s investment portfolio, making the stock its 25th largest position. Puzo Michael J’s holdings in Vertex Pharmaceuticals were worth $6,829,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Activest Wealth Management bought a new position in Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd grew its position in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. Flaharty Asset Management LLC acquired a new stake in Vertex Pharmaceuticals in the 1st quarter worth $32,000. American National Bank & Trust increased its holdings in shares of Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 67 shares during the period. Finally, SJS Investment Consulting Inc. raised its position in shares of Vertex Pharmaceuticals by 46.2% during the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock valued at $46,000 after buying an additional 30 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Up 1.8%

Shares of VRTX opened at $410.28 on Wednesday. The stock has a market cap of $105.19 billion, a PE ratio of 29.33 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The stock has a 50 day simple moving average of $396.79 and a 200-day simple moving average of $441.11.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion for the quarter, compared to analysts’ expectations of $2.90 billion. During the same period in the prior year, the business posted ($12.83) earnings per share. The business’s revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Citigroup increased their target price on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Stifel Nicolaus reduced their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research report on Tuesday, August 5th. Scotiabank decreased their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. JPMorgan Chase & Co. boosted their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an “overweight” rating in a research report on Monday, July 14th. Finally, UBS Group set a $553.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $493.81.

Insider Activity

In other news, Director Bruce I. Sachs purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was purchased at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.